National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-Based screening

Journal of Clinical Oncology

Volumn 33, Issue 22, 2015, Pages 2416-2423

  Drazer, Michael W ^a   Huo, Dezheng ^a   Eggener, Scott E ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; COLONOSCOPY; COMPARATIVE STUDY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; EDUCATIONAL STATUS; HIGH RISK PATIENT; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICARE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PROSTATE CANCER; BLOOD; EARLY DIAGNOSIS; EPIDEMIOLOGY; HEALTH SURVEY; INTERVIEW; MASS SCREENING; METHODOLOGY; MIDDLE AGED; MORTALITY; PRACTICE GUIDELINE; PROCEDURES; PROSTATIC NEOPLASMS; RECALL; RISK; SELECTION BIAS; STANDARDS; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES;

ADULT; AGE FACTORS; AGED; EARLY DETECTION OF CANCER; GUIDELINE ADHERENCE; HEALTH SURVEYS; HUMANS; INTERVIEWS AS TOPIC; LIFE EXPECTANCY; MALE; MASS SCREENING; MENTAL RECALL; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESEARCH DESIGN; RISK; SELECTION BIAS; UNITED STATES;

EID: 84940508147     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.6532     Document Type: Article

References (49)

1. Andriole GL, Crawford ED, Grubb RL 3rd, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319, 2009
2. Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328, 2009
3. Moyer VA, US Preventive Services Task Force: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157:120-134, 2012
4. Wolf AM, Wender RC, Etzioni RB, et al: American Cancer Society guideline for the early detection of prostate cancer: Update 2010. CA Cancer J Clin 60:70-98, 2010
5. Greene KL, Albertsen PC, Babaian RJ, et al: Prostate specific antigen best practice statement: 2009 update. J Urol 182:2232-2241, 2009
6. Qaseem A, Barry MJ, Denberg TD, et al: Screening for prostate cancer: A guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 158:761-769, 2013
7. American Academy of Family Physicians: Clinical Preventive Service Recommendation: Prostate Cancer. http://www.aafp.org/patient-care/clinicalrecommendations/all/prostate-cancer.html
8. Lim LS, Sherin K, ACPM Prevention Practice Committee: Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. Am J Prev Med 34:164-170, 2008
9. Kawachi MH, Bahnson RR, Barry M, et al: NCCN clinical practice guidelines in oncology: Prostate cancer early detection. J Natl Compr Canc Netw 8:240-262, 2010
10. Tasian GE, Cooperberg MR, Cowan JE, et al: Prostate specific antigen screening for prostate cancer: Knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol 30:155-160, 2012
11. Drazer MW, Huo D, Schonberg MA, et al: Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol 29:1736-1743, 2011
12. Drazer MW, Prasad SM, Huo D, et al: National trends in prostate cancer screening among older American men with limited 9-year life expectancies: Evidence of an increased need for shared decision making. Cancer 120:1491-1498, 2014
13. Prasad SM, Drazer MW, Huo D, et al: 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA 307:1692-1694, 2012
14. Harris G: U.S. panel says no to prostate screening for healthy men. The New York Times, 2011. http://www.nytimes.com/2011/10/07/health/07prostate.html?_r=0
15. Kaiser Health News, Kaiser Family Foundation: New England Journal of Medicine weighs in with views on PSA testing. KHN Morning Briefing. 2011. http://kaiserhealthnews.org/morning-breakout/thur-opinion-nejm-on-psa-testing/
16. Bankhead C: Prostate test recommendation draws mixed reviews. MedPage Today, 2011. http://www.medpagetoday.com/HematologyOncology_/ProstateCancer/29015
17. Selyukh A: Health panel takes heat on cancer screening advice. Health, Reuters, 2011. http://www.reuters.com/article/2011/12/18/us-health-taskforce-idUSTRE7BH0C620111218
18. Kane J: PSA testing controversy reignites "overscreening" debate. PBS Newshour, 2011. http://www.pbs.org/newshour/rundown/psa-testing-controversy-reignites-over-screening-debate/
19. Prabhu V, Lee T, Loeb S, et al: Twitter response to the United States Preventive Services Task Force recommendations against screening with prostate specific antigen. BJU Int [epub ahead of print on March 25, 2014]
20. Schonberg MA, Davis RB, McCarthy EP, et al: External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older. J Am Geriatr Soc 59:1444-1451, 2011
21. National Center for Health Statistics: National Health Interview Survey. Public-use data file and documentation. http://www.cdc.gov/nchs/nhis/quest_data_related_1997_forward.htm
22. Cohn JA, Wang CE, Lakeman JC, et al: Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation. Urol Oncol 32:41.e23-41.e30, 2014
23. Aslani A, Minnillo BJ, Johnson B, et al: The impact of recent screening recommendations on prostate cancer screening in a large health care system. J Urol 191:1737-1742, 2014
24. Carter HB, Albertsen PC, Barry MJ, et al: Early detection of prostate cancer: AUA Guideline. J Urol 190:419-426, 2013
25. US Preventive Services Task Force: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 149:185-191, 2008
26. American Society of Clinical Oncology: Choosing Wisely, American Society of Clinical Oncology: 10 things physicians and patients should question. http://www.choosingwisely.org
27. American Geriatrics Society: Choosing Wisely, American Geriatrics Society: 10 things physicians and patients should question. http://www.choosingwisely.org
28. Riedinger CB, Womble PR, Linsell SM, et al: Variation in prostate cancer detection rates in a statewide quality improvement collaborative. J Urol 192:373-378, 2014
29. Womble PR, Montie JE, Ye Z, et al: Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol 67:44-50, 2015
30. Filson CP, Boer B, Curry J, et al: Improvement in clinical TNM staging documentation within a prostate cancer quality improvement collaborative. Urology 83:781-786, 2014
31. Wade J, Rosario DJ, Macefield RC, et al: Psychological impact of prostate biopsy: Physical symptoms, anxiety, and depression. J Clin Oncol 31:4235-4241, 2013
32. Loeb S, Carter HB, Berndt SI, et al: Complications after prostate biopsy: Data from SEER-Medicare. J Urol 186:1830-1834, 2011
33. Nam RK, Saskin R, Lee Y, et al: Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183:963-968, 2010
34. Loeb S, Vellekoop A, Ahmed HU, et al: Systematic review of complications of prostate biopsy. Eur Urol 64:876-892, 2013
35. Gulati R, Tsodikov A, Etzioni R, et al: Expected population impacts of discontinued prostate-specific antigen screening. Cancer 120:3519-3526, 2014
36. Cooperberg MR, Broering JM, Carroll PR: Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117-1123, 2010
37. Gulati R, Gore JL, Etzioni R: Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: Model estimates of potential benefits and harms. Ann Intern Med 158:145-153, 2013
38. Aus G, Damber JE, Khatami A, et al: Individualized screening interval for prostate cancer based on prostate-specific antigen level: Results of a prospective, randomized, population-based study. Arch Intern Med 165:1857-1861, 2005
39. Draisma G, Boer R, Otto SJ, et al: Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95:868-878, 2003
40. Heijnsdijk EA, de Carvalho TM, Auvinen A, et al: Cost-effectiveness of prostate cancer screening: A simulation study based on ERSPC data. J Natl Cancer Inst 107:366, 2015
41. Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA 270:860-864, 1993
42. Eastham JA, Riedel E, Scardino PT, et al: Variation of serum prostate-specific antigen levels: An evaluation of year-to-year fluctuations. JAMA 289:2695-2700, 2003
43. UT Health Science Center: Individualized risk assessment of prostate cancer. http://deb.uthscsa.edu/URORiskCalc/Pages/uroriskcalc.jsp
44. Thompson IM, Ankerst DP, Chi C, et al: Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98:529-534, 2006
45. Parekh DJ, Ankerst DP, Higgins BA, et al: External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 68:1152-1155, 2006
46. Vedder MM, de Bekker-Grob EW, Lilja HG, et al: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol 66:1109-1115, 2014
47. Nordström T, Vickers A, Assel M, et al: Comparison between the four-kallikrein panel and Prostate Health Index for predicting prostate cancer. Eur Urol [epub ahead of print on August 20, 2014]
48. Wei JT, Feng Z, Partin AW, et al: Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol 32:4066-4072, 2014
49. Rauscher GH, Johnson TP, Cho YI, et al: Accuracy of self-reported cancer-screening histories: A meta-analysis. Cancer Epidemiol Biomarkers Prev 17:748-757, 2008